Abstract
A retrospective analysis of 15 renal transplant patients with end-stage renal disease (ESRD) secondary to systemic lupus erythematosus (SLE) was performed. Overall actuarial patient and graft survival at 6 years was 93 and 84%, respectively. Recipients of HLA-identical kidneys did not appear to be at increased risk of allograft failure due to rejection or recurrent disease. Two biopsy-proven cases of recurrent lupus involving the allograft were observed and are discussed. Those patients currently experiencing excellent graft function (creatinine less than 2 mg/dl) had a significantly longer pretransplantation dialytic interval than the group whose most recent serum creatinine exceeds 2 mg/dl (or returned to dialysis). Posttransplantation monitoring of antinuclear antibody, antidouble-stranded DNA, C3, C4, and circulating immune complexes was not predictive of renal or extrarenal disease activity. Renal transplantation should be considered an excellent therapeutic modality for the lupus patient with ESRD, although an interim period on dialysis of at least 1 year seems warranted.
| Original language | English |
|---|---|
| Pages (from-to) | 367-374 |
| Number of pages | 8 |
| Journal | American Journal of Nephrology |
| Volume | 7 |
| Issue number | 5 |
| State | Published - Dec 1 1987 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
Renal transplantation in systemic lupus erythematosus : one center's experience. / Roth, David; Milgrom, M.; Esquenazi, V.; Strauss, J.; Zilleruelo, Gaston E; Miller, J.
In: American Journal of Nephrology, Vol. 7, No. 5, 01.12.1987, p. 367-374.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Renal transplantation in systemic lupus erythematosus
T2 - one center's experience.
AU - Roth, David
AU - Milgrom, M.
AU - Esquenazi, V.
AU - Strauss, J.
AU - Zilleruelo, Gaston E
AU - Miller, J.
PY - 1987/12/1
Y1 - 1987/12/1
N2 - A retrospective analysis of 15 renal transplant patients with end-stage renal disease (ESRD) secondary to systemic lupus erythematosus (SLE) was performed. Overall actuarial patient and graft survival at 6 years was 93 and 84%, respectively. Recipients of HLA-identical kidneys did not appear to be at increased risk of allograft failure due to rejection or recurrent disease. Two biopsy-proven cases of recurrent lupus involving the allograft were observed and are discussed. Those patients currently experiencing excellent graft function (creatinine less than 2 mg/dl) had a significantly longer pretransplantation dialytic interval than the group whose most recent serum creatinine exceeds 2 mg/dl (or returned to dialysis). Posttransplantation monitoring of antinuclear antibody, antidouble-stranded DNA, C3, C4, and circulating immune complexes was not predictive of renal or extrarenal disease activity. Renal transplantation should be considered an excellent therapeutic modality for the lupus patient with ESRD, although an interim period on dialysis of at least 1 year seems warranted.
AB - A retrospective analysis of 15 renal transplant patients with end-stage renal disease (ESRD) secondary to systemic lupus erythematosus (SLE) was performed. Overall actuarial patient and graft survival at 6 years was 93 and 84%, respectively. Recipients of HLA-identical kidneys did not appear to be at increased risk of allograft failure due to rejection or recurrent disease. Two biopsy-proven cases of recurrent lupus involving the allograft were observed and are discussed. Those patients currently experiencing excellent graft function (creatinine less than 2 mg/dl) had a significantly longer pretransplantation dialytic interval than the group whose most recent serum creatinine exceeds 2 mg/dl (or returned to dialysis). Posttransplantation monitoring of antinuclear antibody, antidouble-stranded DNA, C3, C4, and circulating immune complexes was not predictive of renal or extrarenal disease activity. Renal transplantation should be considered an excellent therapeutic modality for the lupus patient with ESRD, although an interim period on dialysis of at least 1 year seems warranted.
UR - http://www.scopus.com/inward/record.url?scp=0023515316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023515316&partnerID=8YFLogxK
M3 - Article
C2 - 3324763
AN - SCOPUS:0023515316
VL - 7
SP - 367
EP - 374
JO - American Journal of Nephrology
JF - American Journal of Nephrology
SN - 0250-8095
IS - 5
ER -